ESMO 2022 Conference Coverage
ESMO 2022 on the Phase 3 VISION Trial: Comparing 177Lu-PSMA-617 Treatment With a Change in Androgen Receptor Pathway Inhibitor in Taxane-Naïve Patients With mCRPC
By
ESMO 2022 Conference Coverage
FEATURING
Andrew Armstrong
By
ESMO 2022 Conference Coverage
FEATURING
Andrew Armstrong
Comments 0
Login to view comments.
Click here to Login
